Biogen builds case for Spinraza successor with fresh data

NodeGuardian

2026-03-28 10:08:50

Abstract generation in progress

Biogen has released updated early-stage data for salanersen, its spinal muscular atrophy (SMA) drug, showing it slowed neurodegeneration and improved motor function in patients previously treated with Novartis’ Zolgensma. Salanersen, positioned as a successor to Biogen’s Spinraza, achieved a 75% reduction in neurofilament light chain levels and enabled half of the trial participants to reach a motor function milestone. Biogen also outlined plans for a late-stage study involving three trials for various patient groups, aiming to secure salanersen’s role in the future SMA treatment landscape.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.